Vitro Diagnostics Inc (fka VODG)

[Potse]

Vitropin commercialization expected during 2013.....

According to the 10-K, commercialization of Vitropin (fertility drug) is expected to occur this year.

Corporate overview section of the VODG website.....

In addition to our stem cell technology and products, Vitro Biopharma holds two US patents with application to the manufacture of follicle-stimulating hormone (FSH), a fertility drug that has been used to treat infertility for over 50 years. During 2011, Vitro licensed two of its patents and certain rights to other related intellectual property to Dr. James Posillico, a renowned expert in Assisted Reproductive Technologies (ART). Dr. Posillico and his team of professionals have recently begun the process of registration of Vitropin™, Vitro’s lead FSH product and related products in certain foreign markets. This registration is being pursued together with the establishment of a separate manufacturing contract and various distribution partnerships. Product marketing, distribution and sales will be managed by an international group of professionals that have considerable expertise in the distribution of similar products in the ART field. The development plan also includes registration for marketing approval of Vitropin™ in several additional countries including the US and EU that collectively represent a multi-billion dollar market.

Through Vitro Biopharma’s license agreement, the company is entitled to certain royalty payments based on sales of Vitropin™. We anticipate contribution of this source of income to our profit and loss statements, especially since this income has minimal associated costs and is mainly transferred to our bottom line. While Vitro Biopharma’s operations are primarily focused on commercialization of its current line of stem cell products and development of a deep pipeline of related products, the company has diligently pursued commercialization of Vitropin™ through its partnership with Dr. Posillico and his team of collaborators.

http://vitrobiopharma.com/about-us/corporate-overview/

James Posillico biographical information.....

Dr. Posillico has an extensive career in the development and commercialization of pharmaceutical products, diagnostics and devices used in the field of assisted reproductive technologies. Following his academic career at Harvard Medical School, he was an executive at Serono, now EMD-Serono, the pioneering leader in the development and sales of fertility drugs. From 1985 to 1993, he held various positions at Serono with responsibility for marketing, clinical development and regulatory issues related to various fertility drugs and pharmaceutical products in other therapeutic areas. Dr. Posillico also served as General Manager of Serono Canada, Inc. with overall P&L responsibility. From 1996 to 2002, Dr. Posillico founded and managed a medical product and device firm, Sage Biopharma that specialized in providing support to assisted reproductive technologies. In 2002, Sage was acquired by Cooper Surgical, Inc, a wholly owned subsidiary of Cooper Companies (NYSE, COO). Dr. Posillico then became Chief Scientific Officer for Cooper Surgical where his responsibilities included business development, primarily in reproductive medicine while providing scientific oversight of acquisitions and licensing. He later founded Molecular Biometrics in 2006, a diagnostic company that developed and launched a product to assess embryo viability in in-vitrofertilization procedures. He is now President and CEO of Translational Technologies, Inc. a biotech firm located in Chester, NJ focused on development of various advanced technologies into commercial products.

http://vitrobiopharma.com/2012/08/28/vitro-biopharma-advances-commercialization-of-its-fertility-drugs-licensing-partner-to-seek-registration-in-international-markets/

2012 10-K.....

We may also engage in additional alliances with other third parties who provide expanded distribution of the Company’s products. The Company focuses its limited resources on product development, manufacture and expansion of its product lines and has only limited available resources for direct sales efforts. Thus the distributors of the Company’s products are an important component of our current sales program. In addition, we continuously work closely with the licensee of our FSH patents to develop business opportunities. We anticipate commercialization of these products during 2013 and additional revenues to the Company from royalty income.

http://knobias.10kwizard.com/filing.php?param=&ipage=8715793&DSEQ=1&SEQ=&SQDESC=SECTION_BODY&exp=